• 대한약침학회지
• /
• 제23권4호
• /
• pp.187-193
• /
• 2020

Objectives: It was aimed to investigate the basic action mechanism of the autoimmune diseases and common features of all diseases. Autoimmune disease are classified organ specific and systemic. Methods: These diseases are seen systemic and disease start locations, origins seem differently. This makes learning and understanding difficult. Autoimmune diseases investigated for easier understanding. It was noticed that, autoimmune diseases' starting places are specific and same all of them. This remarkable point is very important for acupuncture also. So; whole literatüre was researched and important point was found. Results: Whole autoimmune diseases are attack to mesodermal layers and mesodermal origin organs of the body's. The common property of all these disease are same; Diseases start from the mesoderm and mesodermal layer even though their organ origins' belongs to different germ layer. From this point of view, we were able to classify autoimmune diseases simply and it was planned how can we effect body in this context with acupuncture. Conclusion: And, when immunity comes into question, induction of adaptive immunity is depend on antigen presentation to T cells and this situation take place in the lymph node (LN) and also in the skin.When we sank the acupuncture needle into skin, signals create and start mesodermal contacts, during this time mesenchymal origin' autoimmune cells are regulated with this signals.

• The Korean Journal of Physiology and Pharmacology
• /
• 제22권1호
• /
• pp.1-15
• /
• 2018

Inflammasomes are intracellular multiprotein complexes that coordinate anti-pathogenic host defense during inflammatory responses in myeloid cells, especially macrophages. Inflammasome activation leads to activation of caspase-1, resulting in the induction of pyroptosis and the secretion of pro-inflammatory cytokines including interleukin $(IL)-1{\beta}$ and IL-18. Although the inflammatory response is an innate host defense mechanism, chronic inflammation is the main cause of rheumatic diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), and $Sj{\ddot{o}}gren^{\prime}s$ syndrome (SS). Since rheumatic diseases are inflammatory/autoimmune disorders, it is reasonable to hypothesize that inflammasomes activated during the inflammatory response play a pivotal role in development and progression of these diseases. Indeed, previous studies have provided important observations that inflammasomes are actively involved in the pathogenesis of inflammatory/autoimmune rheumatic diseases. In this review, we summarize the current knowledge on several types of inflammasomes during macrophage-mediated inflammatory responses and discuss recent research regarding the role of inflammasomes in the pathogenesis of inflammatory/autoimmune rheumatic diseases. This avenue of research could provide new insights for the development of promising therapeutics to treat inflammatory/autoimmune rheumatic diseases.

• 생명과학회지
• /
• 제13권2호
• /
• pp.236-240
• /
• 2003

인간의 면역계는 외부의 병원균 등의 침입에 대하여 매우 강력한 방어작용을 수행하고 있다. 하지만, 때로 면역계의 손상으로 인해 비정상적인 면역작용이 유발됨으로써 면역성 질환이 야기되기도 한다. 특히, 자가면역 질환은 그 종류가 매우 다양하며 심각한 위험을 초래하기도 한다 이들 질환에 대한 활발한 병인학적 연구가 진행되고 있으나, 아직 정확한 메커니즘을 밝히지는 못하고 있다. 자가면역성 당뇨병의 원인 유전자로 인간의 게놈에 내생하고 있는 HERV가 거론된 후, 사이토카인의 변화나 외생 레트로바기러스의 감염에 의해 HERV의 발현이 활성화되어 superantigen으로 작용함으로써 비정상적인 면역반응이 유도된다는 새로운 사실이 밝혀져 많은 주목을 끌고 있다. 이는 내생 레트로바이러스 유래의 superantigen과 인간의 질병과의 관련성을 비교적명확하게 제시함으로써, 자가면역 질환의 극복을 위한 향후 연구에 주요한 실마리를 제공하고 있다.

• 한국콘텐츠학회논문지
• /
• 제17권7호
• /
• pp.648-663
• /
• 2017

아시아인종에서 GSTM1/GSTT1 유전자 다형성과 자가면역질환과 관련된 감수성을 검증하기 위해, 2015년 12월까지 EMBASE, Google, KISS, MEDLINE, PubMed에 발표된 18편의 논문들을 메타분석에 인용하였다. GSTM1/GSTT1 유전자의 null, present 유형을 개별적으로 분석하였다. 전체 인구에서 GST 다형성과 자가면역질환 사이에 연관성이 발견되었다(GSTM1, OR=1.334, 95% CI=1.137-1.567, p=0.000, GSTT1, OR=1.212, 95% CI=1.012-1.452, p=0.037). 아시아인종에서 자가면역질환, 특히 vitiligo와 아토피 피부염(p<0.05)에서 GSTM1 유전자와의 연관성이 있었고, RA와 SLE에서 GSTT1 유전자와의 연관성은 없었다(p>0.05). GSTM1 null 유형과 GSTT1 present 유형은 아시아인종에서 자가면역질환과 연관이 있었다(p<0.05). 자가면역질환과 GSTM1-GSTT1 다형성 조합 null 유형의 빈도는 대조군보다 높았다. 이와 같이, GSTM1-GSTT1 다형성 조합 null 유형이 아시아인종에서 자가면역질환의 위험 인자가 될 수 있다.

• Parasites, Hosts and Diseases
• /
• 제50권2호
• /
• pp.133-136
• /
• 2012

Visceral leishmaniasis (VL) is a life-threatening infection caused by Leishmania species. In addition to typical clinical findings as fever, hepatosplenomegaly, and cachexia, VL is associated with autoimmune phenomena. To date, VL mimicking or exacerbating various autoimmune diseases have been described, including systemic lupus erythematosus (SLE), rheumatoid arthritis, and autoimmune hepatitis (AIH). Herein, we presented a patient with VL who had overlapping clinical features with SLE, AIH, as well as antimitochondrial antibody (AMA-M2) positive primary biliary cirrhosis.

• Molecules and Cells
• /
• 제42권11호
• /
• pp.747-754
• /
• 2019

The incidence of atherosclerosis is higher among patients with several autoimmune diseases such as psoriasis, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). It is well documented that innate immune cells including macrophages and dendritic cells sense lipid species such as saturated fatty acids and oxidized low-density lipoprotein and produce pro-inflammatory cytokines and chemokines. However, whether a hyperlipidemic environment also impacts autoimmune T cell responses has been unclear. Among $CD4^+$ T cells, Th17 and follicular helper T (Tfh) cells are known to play pathogenic roles in the development of hyperlipidemia-associated autoimmune diseases. This review gives an overview of the cellular and molecular mechanisms by which dysregulated lipid metabolism impacts the pathogenesis of autoimmune diseases, with specific emphasis on Th17 and Tfh cells.

• IMMUNE NETWORK
• /
• 제22권5호
• /
• pp.37.1-37.16
• /
• 2022

Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with monoclonal Abs targeting B cell lineage markers is standard care therapy for several B cell-mediated autoimmune disorders. In the last 5 years, genetically-engineered cellular immunotherapies targeting B cells have shown superior efficacy and long-term remission of B cell malignancies compared to historical clinical outcomes using B cell depletion with monoclonal Ab therapies. This has raised interest in understanding whether similar durable remission could be achieved with use of genetically-engineered cell therapies for autoimmunity. This review will focus on current human clinical trials using engineered cell therapies for B cell-associated autoimmune diseases.

• Annals of Clinical Neurophysiology
• /
• 제3권1호
• /
• pp.21-25
• /
• 2001

Background & Object : Myasthenia gravis(MG) is an autoimmune disease due to binding of antibody to acetylcholine receptors on the muscle membrane. It is well known that other autoimmune diseases infrequently accompany myasthenia gravis. The aim of this study was to evaluate the clinical significance of associated autoimmune diseases(AAD) and compare prognosis between MG with AAD and MG without AAD. Method : A total of 65 MG patients(24 men and 41 women) were enrolled at this study. From the clinical records of these patients, we investigated the clinical characteristics and prognosis of MG with AAD and compared these data with those of MG without other such diseases. Results : AAD were found in 10 of 65 cases(15%). 9 cases of 10 MG with AAD were generalized MG type. The most common disease was thyroid disorder. The rate of AAD was higher in thymic abnormal patients. There was no significant remission rate difference between MG with AAD and MG without AAD, but the percentage of patients experienced crisis was higher in MG with AAD. Conclusion : The occurrence of AAD may suggest a more generalized autoimmune disturbance that could be associated with a less favorable prognosis.

• IMMUNE NETWORK
• /
• 제22권1호
• /
• pp.9.1-9.23
• /
• 2022

In the past few decades, biological drugs and small molecule inhibitors targeting inflammatory cytokines, immune cells, and intracellular kinases have become the standard-of-care to treat autoimmune diseases. Inhibition of TNF, IL-6, IL-17, and IL-23 has revolutionized the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis. B cell depletion therapy using anti-CD20 mAbs has shown promising results in patients with neuroinflammatory diseases, and inhibition of B cell survival factors is approved for treatment of systemic lupus erythematosus. Targeting co-stimulatory molecules expressed on Ag-presenting cells and T cells is also expected to have therapeutic potential in autoimmune diseases by modulating T cell function. Recently, small molecule kinase inhibitors targeting the JAK family, which is responsible for signal transduction from multiple receptors, have garnered great interest in the field of autoimmune and hematologic diseases. However, there are still unmet medical needs in terms of therapeutic efficacy and safety profiles. Emerging therapies aim to induce immune tolerance without compromising immune function, using advanced molecular engineering techniques.

• IMMUNE NETWORK
• /
• 제8권4호
• /
• pp.107-123
• /
• 2008

It has now been well documented in a variety of models that T regulatory T cells (Treg cells) play a pivotal role in the maintenance of self-tolerance, T cell homeostasis, tumor, allergy, autoimmunity, allograft transplantation and control of microbial infection. Recently, Treg cell are isolated and can be expanded in vitro and in vivo, and their role is the subject of intensive investigation, particularly on the possible Treg cell therapy for various immune-mediated diseases. A growing body of evidence has demonstrated that Treg cells can prevent or even cure a wide range of diseases, including tumor, allergic and autoimmune diseases, transplant rejection, graft-versus-host disease. Currently, a large body of data in the literature has been emerging and provided evidence that clear understanding of Treg cell work will present definite opportunities for successful Treg cell immunotherapy for the treatment of a broad spectrum of diseases. In this Review, I briefly discuss the biology of Treg cells, and summarize efforts to exploit Treg cell therapy for autoimmune diseases. This article also explores recent observations on pharmaceutical agents that abrogate or enhance the function of Treg cells for manipulation of Treg cells for therapeutic purpose.